BR112019009726A2 - terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica - Google Patents

terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica

Info

Publication number
BR112019009726A2
BR112019009726A2 BR112019009726A BR112019009726A BR112019009726A2 BR 112019009726 A2 BR112019009726 A2 BR 112019009726A2 BR 112019009726 A BR112019009726 A BR 112019009726A BR 112019009726 A BR112019009726 A BR 112019009726A BR 112019009726 A2 BR112019009726 A2 BR 112019009726A2
Authority
BR
Brazil
Prior art keywords
atherosclerosis
pcsk9
ldl
therapies
cardiovascular disease
Prior art date
Application number
BR112019009726A
Other languages
English (en)
Inventor
Honarpour Narimon
Mudalinayake Somaratne Ransi
Andrew Donald Scott Robert
Wasserman Scott
Nicholls Stephen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60484496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019009726(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112019009726A2 publication Critical patent/BR112019009726A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a presente invenção refere-se a combinações de terapias que proporcionam o tratamento, incluindo regressão, da aterosclerose e/ou melhoria de resultados cardiovasculares. genericamente descrito, isto inclui um primeiro agente de redução de ldl-c não-pcsk9 (tal como uma estatina ou outra terapia de redução de ldl-c de não pcsk9), combinado com uma segunda terapia com inibidor de pcsk9 (tal como um anticorpo pcsk9 ou anti-rna). a aplicação de ambas as terapias, a níveis adequadamente elevados de forma a reduzir o nível de ldl-c do sujeito a níveis muito baixos, durante um período de tempo adequado, foi determinada como proporcionando um benefício adicional de proteção suplementar contra a aterosclerose, melhorando os resultados cardiovasculares de um sujeito.
BR112019009726A 2016-11-14 2017-11-13 terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica BR112019009726A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662421685P 2016-11-14 2016-11-14
US201762471874P 2017-03-15 2017-03-15
US201762515117P 2017-06-05 2017-06-05
US201762581244P 2017-11-03 2017-11-03
US201762584600P 2017-11-10 2017-11-10
PCT/US2017/061346 WO2018089912A2 (en) 2016-11-14 2017-11-13 Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease

Publications (1)

Publication Number Publication Date
BR112019009726A2 true BR112019009726A2 (pt) 2019-08-13

Family

ID=60484496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019009726A BR112019009726A2 (pt) 2016-11-14 2017-11-13 terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica

Country Status (17)

Country Link
US (1) US20200368350A1 (pt)
EP (1) EP3538149A2 (pt)
JP (2) JP2019533715A (pt)
KR (1) KR20190085963A (pt)
CN (1) CN110234350A (pt)
AU (1) AU2017356219A1 (pt)
BR (1) BR112019009726A2 (pt)
CA (1) CA3043700A1 (pt)
CL (2) CL2019001304A1 (pt)
CO (1) CO2019004814A2 (pt)
IL (1) IL266579A (pt)
JO (1) JOP20190112A1 (pt)
MA (1) MA46758A (pt)
MX (1) MX2019005627A (pt)
TN (1) TN2019000156A1 (pt)
WO (1) WO2018089912A2 (pt)
ZA (1) ZA201902975B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
AU2019315823A1 (en) * 2018-07-31 2021-04-01 Wen Tan New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
WO2021012074A1 (en) * 2019-07-19 2021-01-28 Ebay Inc. Sample delta monitoring
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2835429B1 (en) 2006-05-11 2017-12-13 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9493774B2 (en) * 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
MX2011013421A (es) 2009-06-15 2012-03-16 Alnylam Pharmaceuticals Inc Arnds formulado con lipido de direccionamiento del gen pcsk9.
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2655419A1 (en) 2010-12-22 2013-10-30 F.Hoffmann-La Roche Ag Anti-pcsk9 antibodies and methods of use
JP2014511378A (ja) 2011-02-11 2014-05-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｃｓｋ９アンタゴニスト
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
WO2016112337A1 (en) * 2015-01-09 2016-07-14 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
EA039310B1 (ru) * 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска

Also Published As

Publication number Publication date
WO2018089912A3 (en) 2018-06-21
CA3043700A1 (en) 2018-05-17
EP3538149A2 (en) 2019-09-18
WO2018089912A2 (en) 2018-05-17
CO2019004814A2 (es) 2019-07-31
JP2019533715A (ja) 2019-11-21
US20200368350A1 (en) 2020-11-26
ZA201902975B (en) 2020-01-29
IL266579A (en) 2019-07-31
MA46758A (fr) 2019-09-18
CL2019001304A1 (es) 2019-09-23
CN110234350A (zh) 2019-09-13
KR20190085963A (ko) 2019-07-19
CL2020002993A1 (es) 2021-05-14
AU2017356219A1 (en) 2019-05-30
JP2023071715A (ja) 2023-05-23
JOP20190112A1 (ar) 2019-05-14
MX2019005627A (es) 2019-10-14
TN2019000156A1 (en) 2020-10-05

Similar Documents

Publication Publication Date Title
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
EA201790398A1 (ru) Способы лечения заболевания печени
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
CL2019001047A1 (es) Metodo para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9).
CL2020000384A1 (es) Métodos para tratar y/o prevenir la enfermedad de injerto contra huésped y/o hemorragia alveolar difusa y/o enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
ECSP20082339A (es) Moduladores de la expresión de apol1
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
BR112017018758A2 (pt) alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide
CO2020008769A2 (es) Moduladores de la expresión dnm2
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]